Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of EGFR (Epidermal Growth Factor Receptor) inhibitor in preparation of medicine for treating JE (Japanese Encephalitis)

A Japanese encephalitis and inhibitor technology, applied in the field of medicine, can solve problems such as no literature reports on the effect of EGFR inhibitors, and achieve the effect of good market value and clinical application prospects

Active Publication Date: 2016-06-22
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no literature report on the role of EGFR inhibitors in the treatment of Japanese encephalitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of EGFR (Epidermal Growth Factor Receptor) inhibitor in preparation of medicine for treating JE (Japanese Encephalitis)
  • Application of EGFR (Epidermal Growth Factor Receptor) inhibitor in preparation of medicine for treating JE (Japanese Encephalitis)
  • Application of EGFR (Epidermal Growth Factor Receptor) inhibitor in preparation of medicine for treating JE (Japanese Encephalitis)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] 1. Experimental materials

[0025] Erlotinib is an epidermal growth factor receptor inhibitor.

[0026] Human neuroblastoma line SK-N-SH, purchased from ATCC, accession number: ATCCHTB-11.

[0027] 2. Experimental method

[0028] 1 siRNA interference

[0029] 1.1 RNA transfection

[0030] Refer to Lipofectamine2000 instructions for transfection steps

[0031] 1) 12-16 hours in advance, SK-N-SH cells (purchased from ATCC, deposit number: ATCCHTB-11) were plated and cultured on a 24-well cell culture plate so that the cell density during transfection was 80%-90%.

[0032] 2) Take 2μL of Lipofectamine2000 into 50μL of opti-MEM and mix gently, incubate at room temperature for 5 minutes; take another 5μL of 5μM interfering RNA and mix with 50μL of opti-MEM. After the incubation, add the diluted Lipofectamine2000 transfection reagent to the diluted RNA, and gently pipette to mix. After incubating at room temperature for 20 min, add to SK-N-SH cells and supplement with 400 μL opti-MEM to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicament, in particular to application of an EGFR (Epidermal Growth Factor Receptor) inhibitor in preparation of medicine for treating JE (Japanese Encephalitis). According to the application of the EGFR inhibitor in preparation of the medicine for treating JE, provided by the invention, an important function of the EGFR in JEV (Japanese Encephalitis Virus) infection is discovered, and the EGFR inhibitor has the characteristic of inhibiting the JEV infection; furthermore, the situation that the EGFR inhibitor is capable of influencing the JEV infection through inhibiting phosphorylation of the EGFR is discovered. According to the application of the EGFR inhibitor in preparation of the medicine for treating JE, provided by the invention, the novel medicine is provided for preventing and treating JE, and the market value and a clinic application prospect are better.

Description

Technical field [0001] The invention relates to the technical field of medicine, in particular to the application of an epidermal growth factor receptor inhibitor in the preparation of drugs for treating Japanese encephalitis. Background technique [0002] Japanese encephalitis (JE) is also known as Japanese encephalitis, or Japanese encephalitis for short. It is widespread in parts of East Asia, Southeast Asia, South Asia and Western Pacific including China. Japanese encephalitis virus (JEV), also known as Japanese encephalitis virus, is the causative agent of Japanese encephalitis. It mainly infects children. It often causes central nervous system infection and can lead to death in severe cases. Japanese encephalitis virus belongs to the genus of Flavivirus, Flaviviridae. The Flaviviridae virus is a positive-strand RNA virus with about 11,000 nucleic acids. The virus particle includes 3 structural proteins, namely capsid protein (C) and front membrane protein. (prM) and glyco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/517A61P31/20
CPCA61K9/0019A61K31/517Y02A50/30
Inventor 朱勇喆戚中田徐庆强朱耐伟谭雨豪吴月明
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com